Vanda Pharmaceuticals ($VNDA): Positive HETLIOZ Phase 3 Results in DSWPD

01 Scenario map, sentiment and what to watch

Constructive scenario: new launches and Fanapt growth offset HETLIOZ pressure while expenses moderate, Quimilza is approved on or before December 12, 2026 with a workable label, and the HETLIOZ delayed sleep-wake phase disorder application reaches the FDA. Cautious scenario: slower uptake, additional funding needs or regulatory setbacks, such as a complete response letter for Quimilza, a NEREUS ramp that stays at the low end of its range or a quarterly cash drawdown that does not narrow. Merlintrader does not assign an outcome probability.

Retail sentiment as of October 2, 2026. The views summarised here are those of traders and non-professional investors on Stocktwits, Reddit and X, not of analysts. On Stocktwits the normalized sentiment score for $VNDA stood at 91 out of 100, in the “extremely bullish” band, with message volume in the “extremely high” band (87 out of 100) and 5,464 watchers. The one-month series shows how fast that reading moves: between 75 and 84 in early September, 32 to 36 from September 14 to September 21, 42 on September 29 and 88 on September 30, the first full session after the HETLIOZ Phase 3 announcement.

The themes are consistent. The most frequent is the gap between positive regulatory and clinical news and the share-price reaction, with several users asking why a positive Phase 3 was followed by selling. Others blame cash burn and management, speculate about a future equity raise or at-the-market sales, or argue that the company should be sold; a minority describes a run-up into the December decision. For reference, the filings show a $200 million mixed shelf, which is registered capacity rather than an at-the-market programme or cash raised. On X, the most-engaged posts in the same reading debated the small delayed sleep-wake phase disorder sample, 20 patients per arm, and part of the cashtag traffic consisted of invitations to promotional messaging groups rather than analysis. Reddit discussion was thin.

What to watch: BYSANTI commercial availability in the second half of 2026; the Thetis Phase 3 topline, guided by the company for 2026 (registry primary completion estimated December 1, 2026); the third-quarter report; the December 12 Quimilza target action date; the December HETLIOZ jet-lag hearing; the delayed sleep-wake phase disorder sNDA submission; and the BYSANTI major depressive disorder topline guided to the first half of 2027. Sentiment readings measure attention and change within hours; they do not measure demand, approval or value.

What Would Falsify This Reading

Merlintrader reads Vanda as a company with real revenue and a thinning cash position, buying optionality with a wide regulatory pipeline while its established products decline. The following observations would require reassessing the relevant assumptions and are checkable against primary documents.

• Quimilza receives an adverse regulatory decision or material review delay. The biologics license application for imsidolimab in generalized pustular psoriasis is the one hard-dated regulatory item on the calendar, on a pivotal study published in NEJM Evidence on April 28, 2026. A complete response letter could delay or prevent this proposed revenue diversification, depending on its reasons and the feasibility of a response.
• The cash line keeps falling at the first-half rate. Cash and marketable securities went from $263.8 million at December 31, 2025 to $170.0 million at June 30, 2026, with $81.3 million of operating cash use in the half against $48.4 million a year earlier. Two more halves at that rate would use approximately $162.6 million before other cash movements, making financing capacity and spending changes increasingly important.
• Commercial contribution deteriorates relative to spending. Q2 product sales were $50.5 million against R&D of $37.0 million and SG&A of $71.8 million. Revenue already falls short of these expenses. Further erosion without offsetting growth or cost changes could increase funding pressure.
• The HETLIOZ sNDA does not reach the agency, or is refused filing. The September 29, 2026 Phase 3 result in delayed sleep-wake phase disorder was positive on its primary endpoint, with sleep onset advanced 37.1 minutes more than placebo, p=0.022, in the 40 patients in the reported primary analysis of 43 enrolled. Vanda has said it intends to file a supplemental application and has announced no date. The company’s regulatory history with this agency, including the jet-lag refusal and the resulting litigation, is why the intention and the filing are kept as separate facts.

None of these is a prediction. They identify assumptions to reassess against subsequent disclosures rather than treating the analysis as fixed.

02 Imsidolimab: EU designation and U.S. review

The August 24 announcement confirms European Commission orphan designation for imsidolimab in generalized pustular psoriasis. Designation provides development incentives and potential post-approval exclusivity; it is not marketing authorization. Vanda reports the U.S. BLA remains under review with December 12, 2026 target action date. U.S., Japanese and EU orphan designations do not guarantee a positive FDA decision.

03 August 5, 2026 update: Q2 delivers a split commercial signal and confirms the cash test

Vanda Pharmaceuticals reported second-quarter 2026 total net product sales of $50.5 million, down 4% from $52.6 million in Q2 2025. The headline needs an important timing qualification: approximately $7.0 million of HETLIOZ orders shipped on June 29 arrived on July 1 and therefore will be recognized in Q3 rather than Q2. Even with that timing effect, the quarter reinforces that Vanda’s portfolio is moving through a difficult transition in which Fanapt growth and new launches must offset HETLIOZ erosion and a very large investment burden.

The strongest operating evidence came from Fanapt. Q2 net product sales reached $36.0 million and total prescriptions increased 31% year over year. Since the bipolar I expansion, Vanda says total prescriptions are 62% above Q2 2024 and new-to-brand prescriptions are up 300%. That makes Fanapt the clearest bridge between the legacy commercial base and the next launch cycle.

NEREUS recorded $1.0 million in its first reported commercial quarter. The early launch used a direct-to-consumer web portal beginning in May, with personal promotion expected later in 2026. One million dollars is enough to confirm that the asset has entered the revenue statement, but it is not enough to establish the trajectory. Vanda maintained a broad full-year NEREUS range of $10 million to $30 million, so conversion must accelerate materially in the second half for the midpoint or high end to become credible.

HETLIOZ is the main commercial weakness. Reported Q2 sales fell to $5.6 million from $16.2 million. The $7.0 million shipment timing issue matters: if recognized in Q2, it would have produced a very different quarterly comparison and lifted total product sales above the reported level. But those orders are a timing bridge, not a cure for generic erosion. Investors still need to track the normalized sales base after the Q3 recognition.

Expenses are the other critical line. R&D rose to $37.0 million from $22.0 million and SG&A reached $71.8 million from $64.6 million, driving a net loss of $62.5 million versus $27.2 million one year earlier. Management expects operating expenses to begin moderating by the end of 2026 and more substantially in 2027 as Phase 3 work, launch preparation and commercial-supply manufacturing conclude. That is now a central assumption rather than a footnote: with $170.0 million of cash and securities at June 30, the company says resources should fund operations through at least the end of 2027, but the path requires both revenue delivery and expense moderation.

The August 5 release guided to three Phase 3 readouts by year-end. HETLIOZ DSWPD results were subsequently announced on September 29 and are no longer pending. The earlier guidance for NEREUS in GLP-1-associated vomiting and the BYSANTI launch in H2 remains dated company guidance; the VQW-765 Phase 3 in social anxiety disorder reported on October 14, 2026 and missed its primary endpoint. The December 12 imsidolimab PDUFA and the expected December HETLIOZ jet-lag hearing are separate regulatory matters.

04 Fast facts and current market snapshot

Finviz Elite data as of October 2, 2026: market capitalization $290.29 million; previous close $4.81 for October 1; Finviz shares 60.45 million, float 57.20 million, short float 14.85%, short interest 8.50 million shares, days to cover 8.95, institutional ownership 85.55%, insider ownership 5.40%. October 2 is the reading date, not a short-interest settlement date. These third-party aggregates can overlap and lag filings. Separately, the SEC Q2 10-Q cover reports 60,462,687 common shares outstanding July 30, 2026, versus 60,454,687 June 30. SEC Q2 10-Q.

05 Commercial engine: revenue base and launch execution

The June 10-Q states BYSANTI data exclusivity runs through February 20, 2031 and the latest of its listed patents expires May 31, 2044. Data exclusivity and patent protection are separate mechanisms; the stated dates do not guarantee freedom from challenge or competition. Vanda Pharmaceuticals Q2 2026 Form 10-Q.

Q1 2026 revenue mix: Fanapt still carries the commercial base

Net product sales by brand

Quarter ended March 31, 2026. Total net product sales: $51.7 million. Only Fanapt, HETLIOZ and PONVORY contributed in Q1; NEREUS launched May 1 and BYSANTI had not yet launched. Percentages are calculated from company-reported figures and rounded.

Fanapt represented roughly 57% of Q1 product sales and remains the financial bridge into the new launch cycle. HETLIOZ still matters, but its 24% year-over-year decline makes replacement revenue from NEREUS and, later, BYSANTI strategically important.

Commercial portfolio: what pays the bills

Fanapt: the current commercial pillar

Fanapt, or iloperidone, remains Vanda’s most important commercial asset. In Q1 2026, Fanapt net product sales were $29.6 million, up 26% year over year. Vanda also reported strong prescription momentum, with total prescriptions up 32% and new-to-brand prescriptions up 76% versus Q1 2025. In April 2026, weekly Fanapt TRx reached an 11-year high of more than 2,600 prescriptions for the week ending April 24.

The risk is durability. Fanapt is an older atypical antipsychotic in a crowded market with generics and newer branded competitors. The market will keep watching patent and exclusivity dynamics. If generic erosion begins before BYSANTI and NEREUS scale, Vanda’s revenue mix could become more fragile. This is one reason why BYSANTI’s commercial differentiation matters so much: investors need to understand whether BYSANTI can extend or refresh the CNS franchise, or whether it mostly overlaps with Fanapt economics.

HETLIOZ: still meaningful, but under pressure

HETLIOZ, or tasimelteon, is approved in the United States for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances associated with Smith-Magenis Syndrome. It was once Vanda’s defining product, but the story has changed. Sales have been pressured by generics and by regulatory setbacks in attempted label expansion. In Q1 2026, HETLIOZ net product sales were $15.9 million, down 24% year over year.

The jet lag disorder effort remains an unusual regulatory and legal case. In January 2026, Vanda said the FDA issued a decision letter concluding that the HETLIOZ sNDA for jet lag disorder could not be approved in its current form. The FDA acknowledged positive efficacy from controlled clinical trials, according to Vanda’s release, but concluded that the data did not provide substantial evidence of effectiveness for jet lag disorder, mainly because controlled phase-advance protocols were not considered sufficiently analogous to actual jet travel.

The story did not end there. On June 3, 2026, the Federal Register published a notice that the FDA was announcing a formal evidentiary public hearing on the proposal to refuse approval of the HETLIOZ sNDA for jet lag disorder. The hearing is not the same as an approval. It does not mean Vanda will win. But it does keep the matter alive and highlights the unusual nature of Vanda’s regulatory posture. For the equity story, HETLIOZ is now both a declining cash-flow asset and an active legal-regulatory subplot.

PONVORY: small, growing, and strategically useful

PONVORY, or ponesimod, is an oral S1P receptor modulator for relapsing multiple sclerosis. Vanda acquired U.S. and Canadian rights from Janssen, adding an anti-inflammatory franchise to a company historically associated with CNS and sleep. In Q1 2026, PONVORY net product sales were $6.2 million, up 10% year over year.

BYSANTI: second approval, but not a simple second Fanapt

BYSANTI, or milsaperidone, was approved by the FDA on February 20, 2026 for schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. Vanda describes BYSANTI as a new chemical entity in the atypical antipsychotic class. The FDA approval relied on a pharmacokinetic bridge to Fanapt rather than a wholly separate large pivotal efficacy program: BYSANTI demonstrated bioequivalence to iloperidone across the therapeutic dosing spectrum, allowing the application to leverage established knowledge from the Fanapt development program and extensive real-world experience with iloperidone.

On the negative side, differentiation is the key question. Reuters reported that Jefferies analyst Andrew Tsai questioned how BYSANTI sales will shape up given that it is essentially similar to Fanapt in safety and efficacy, and that this raises the question of why patients would choose BYSANTI, especially if Fanapt faces generic competition around late 2027 or 2028. Reuters also cited his model of BYSANTI sales of about $200 million by 2033. That number is useful as a market reference, but the more important point is the debate behind it.

The launch timing is also relevant. Vanda said it anticipates commercial availability in H2 2026. That means the Q2 and Q3 financial reports may still show mostly launch preparation rather than meaningful BYSANTI revenue. Investors will likely watch management commentary carefully: number of covered lives, early formulary access, prescriber awareness, sampling strategy, gross-to-net assumptions and any interaction with Fanapt trends.

BYSANTI also has a Phase 3 expansion program as a once-daily adjunctive treatment for major depressive disorder. In its August 5 Q2 update, Vanda said topline results were expected in H1 2027. That is a company target rather than a guaranteed date, but it adds a post-2026 clinical catalyst and could broaden the commercial opportunity if the trial succeeds and a supplemental filing follows.

06 Pipeline and regulatory catalysts

HETLIOZ Phase 3 meets the sleep-onset primary endpoint. The September 29 release reports the randomized, double-blind, placebo-controlled Phase 3 study VP-VEC-162-3502 (NCT04652882), with once-daily tasimelteon 20 mg for 28 days in adults aged 18–75. Vanda enrolled 43 patients across 26 sites over more than five years; the reported efficacy groups contain 20 patients each. The primary endpoint, sleep-episode start time measured by diary, advanced 42.5 minutes with HETLIOZ versus 5.4 with placebo: a 37.1-minute difference (p=0.022). The release does not explain the difference between 43 enrolled and the 40 patients in these groups.

The exploratory responder analysis found an advance of at least 30 minutes in 12/20 patients (60%) versus 3/20 (15%), p=0.008. It is an exploratory analysis, not a second primary endpoint. Vanda reported no new safety signals during the 28-day controlled period. The small sample, short follow-up and reliance on a sleep diary limit the conclusions that can be drawn from this topline announcement.

Vanda intends to discuss the data with the FDA and submit an sNDA. This announcement confirms neither submission nor acceptance or approval, and sets no DSWPD PDUFA date. It is separate from the HETLIOZ jet-lag hearing and the December 12, 2026 imsidolimab review. The efficacy and safety figures currently come from the issuer’s release; ClinicalTrials.gov independently documents the study design, but its older registry record does not verify these newly announced results. Issuer release · ClinicalTrials.gov NCT04652882

NEREUS: the approved motion-sickness asset becomes a launch story

NEREUS (tradipitant), licensed from Eli Lilly, is an oral NK-1 antagonist approved to prevent motion-induced vomiting in adults. It targets the substance P/NK-1 pathway. Its safety information also warns of drowsiness and fatigue and possible impairment of driving or machinery use, with greater risk alongside CNS depressants or CYP3A4 inhibitors. A different mechanism does not mean freedom from sedation. Company launch and safety information.

The December 30, 2025 approval was important because motion sickness had not seen a new pharmacologic treatment for decades. The approval was supported by real-world provocation studies on boats. In the Motion Syros study, Vanda reported vomiting incidence of 18.3–19.5% with NEREUS versus 44.3% with placebo. In Motion Serifos, vomiting rates were 10.4–18.3% with NEREUS versus 37.7% with placebo. Across the program, the company emphasized risk reductions of more than 50–70% and a favorable safety profile consistent with acute use.

Commercially, the May 1, 2026 launch is the real test. Vanda made NEREUS available by prescription through retail pharmacies nationwide and through a dedicated direct-to-consumer portal at nereus.us. The DTC model matters because motion sickness is a consumer-facing condition. Patients may think about it before cruises, boating trips, flights, amusement parks, military transport, space-related motion environments or other high-motion settings. A traditional specialty-pharma sales model may not be enough. Vanda appears to be trying to reduce access friction through online ordering and direct home delivery.

The pricing strategy also matters. Vanda announced a cash-pay price of $85 per dose through the DTC portal, compared with a standard list price of $255 per dose. This creates a two-channel market: reimbursed prescription access through conventional routes and a cash-pay path for motivated patients. The question is whether enough patients view prevention of motion-induced vomiting as worth that out-of-pocket price, especially when older OTC or generic options are cheaper. For severe patients, the answer may be yes. For occasional mild users, the answer may be no.

The risk is that motion sickness can be episodic, seasonal and difficult to convert into repeat prescription revenue. A patient may need a dose before a boat trip, not chronic monthly therapy. That affects revenue cadence, inventory planning, advertising efficiency and payer strategy. NEREUS may ultimately be a meaningful specialty product, but the market should not treat approval as equivalent to automatic blockbuster adoption.

The Thetis study: VNDA’s GLP-1 adjacency

On April 8, 2026, Vanda announced initiation of Thetis, a multicenter, randomized, double-blind, placebo-controlled trial of oral tradipitant in patients initiated at a high dose of a GLP-1 receptor agonist. The primary endpoint is the proportion of patients free from vomiting episodes during the treatment period. ClinicalTrials.gov lists approximately 280 participants, a recruiting status and estimated primary completion on December 1, 2026. Vanda expects topline results during 2026, but that remains company guidance rather than a guaranteed date. The company also cautioned that additional study data may be required before approval of a supplemental NDA or new application for this use.

The prior signal is worth noting. Vanda reported that a previous Phase 2 study met its primary endpoint, with 29.3% of tradipitant-treated participants experiencing vomiting compared with 58.6% on placebo. That represented a 50% relative reduction. The study also met a key secondary endpoint involving vomiting and significant nausea. These numbers are compelling enough to justify further work, but they do not remove the need for confirmatory evidence, label negotiation, safety review and a clear regulatory path.

Imsidolimab: December 12 PDUFA plus expanding global orphan positioning

Imsidolimab may become the most important remaining 2026 FDA event for Vanda. The FDA accepted the BLA for imsidolimab in generalized pustular psoriasis, or GPP, and assigned a target action date of December 12, 2026. GPP is a rare, chronic and potentially life-threatening autoinflammatory skin disorder characterized by sudden flares of widespread pustules, erythema and systemic symptoms such as fever and fatigue. The disease is associated with dysregulation of the IL-36 pathway and is clinically distinct from plaque psoriasis.

Imsidolimab is a high-affinity humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling. Vanda holds an exclusive global license from AnaptysBio to develop, manufacture and commercialize the asset. Under the agreement disclosed in Vanda’s Q1 10-Q, Anaptys may receive a 10% royalty on global net sales and up to $35 million of remaining regulatory and sales milestones, including $5 million for the first U.S. approval and $5 million for the first EU marketing authorization.

In GEMINI-1, 53% receiving a single 750 mg intravenous dose achieved clear/almost-clear skin (GPPPGA 0/1) at Week 4 versus 13% on placebo (company-reported p=0.0131). Maintenance evaluated responders re-randomized after induction: eight received active maintenance and eight placebo. The company reported no flares among the eight active-maintenance patients, with follow-up up to 104 weeks in GEMINI-2; this does not describe all 45 initial participants or two complete years for every patient. The company releases reported p=0.0131, whereas the published abstract reports p=0.023 for each active-dose comparison; the abstract does not explain that difference. The FDA benefit-risk and manufacturing review remains unresolved. BLA submission and study description.

From the July 16 COMP opinion to the August 24 European Commission designation

On July 16, Vanda announced that the EMA’s Committee for Orphan Medicinal Products, or COMP, had adopted a positive opinion recommending orphan designation for imsidolimab in GPP. On August 24, the European Commission granted the designation, completing the two-step procedure. This adds formal European recognition to the U.S. and Japanese orphan framework. It does not authorize sales in Europe and does not predict the FDA decision.

Commercial execution would remain demanding even after approval. GPP is rare, so uptake depends on rapid diagnosis, specialist awareness, treatment-site readiness, reimbursement, patient identification and speed of treatment. Because imsidolimab is a biologic, CMC and supply-chain readiness matter alongside clinical efficacy. The clean investor framing is therefore: global orphan validation has improved, but December 12 remains the decisive U.S. regulatory hinge.

VCA-894A: the July 7 rare pediatric designation

On July 7, 2026, Vanda announced that the FDA granted Rare Pediatric Disease Designation to VCA-894A, its investigational antisense oligonucleotide therapy for Charcot-Marie-Tooth disease, axonal, type 2S. The designation was granted by the FDA’s Office of Orphan Products Development and Office of Pediatric Therapeutics. Vanda said CMT2S is a serious inherited neuromuscular disorder that progressively leads to muscle weakness and loss of motor function, with an estimated prevalence below one in one million worldwide.

VCA-894A is a 2′-O-methoxyethyl phosphorothioate oligonucleotide sodium salt that specifically targets a cryptic splice site variant within IGHMBP2. This is highly specialized medicine. Vanda said the therapeutic target is a unique variant of CMT2S not yet observed in any other patient. That makes the program scientifically interesting but also commercially unusual. It is not a classic mass-market drug development program. It is closer to a personalized or ultra-orphan genetic intervention.

The designation matters because the Rare Pediatric Disease Priority Review Voucher program can create potential value if a sponsor ultimately obtains approval of a qualifying marketing application and meets statutory requirements. A priority review voucher can be sold or used, and historically these vouchers have had meaningful economic value. However, investors should not over-model this. The designation itself is not approval, does not prove efficacy and does not guarantee voucher eligibility. It simply recognizes that the disease and program may qualify under the rare pediatric framework.

For the VNDA story, the July 7 news is best treated as pipeline validation and optionality. It does not change the near-term revenue model. It does not solve cash burn. It does not replace NEREUS, BYSANTI or imsidolimab as the primary drivers. But it reinforces Vanda’s identity as a company willing to pursue genetics-informed, rare and difficult indications.

VQW-765: Phase 3 missed its primary endpoint; program on hold

Vanda reported that Study 3201 (NCT07221578) did not meet its primary endpoint. The Phase III trial tested a single oral dose of VQW-765, an alpha 7 nicotinic receptor partial agonist, for on-demand treatment of acute anxiety in adults with social anxiety disorder. Participants were randomized 1:1 at about 30 U.S. sites. The primary endpoint was distress during the performance phase of the Trier Social Stress Test in women, measured on the 0–100 Subjective Units of Distress Scale: 65.6 on VQW-765 versus 66.0 on placebo, a difference of −0.4 points (95% CI −5.32 to 4.62; p=0.8899). The key secondary endpoint, in men and women combined, also failed (64.7 versus 63.8; p=0.6605). The drug was safe and well tolerated, but the results did not confirm the earlier Phase II signal in performance anxiety. Vanda placed the VQW-765 program on hold pending further analysis of the full dataset. The study randomized 546 adults, above the 500 estimated in the registry. The release does not address the December 12, 2026 FDA target date for Quimilza (imsidolimab) or the Thetis study. Vanda press release, October 14, 2026

VQW-765 Phase 3 results were announced on October 14, 2026. The Thetis registry record (NCT07446439), last posted April 20, lists recruiting status, a target of 280 participants and estimated completion on December 1, 2026; that date is not a promised result-release date. Company August guidance called for three readouts during 2026; HETLIOZ DSWPD was reported September 29 and VQW-765 on October 14, 2026 (primary endpoint missed); Thetis remains pending. BYSANTI MDD remains guided for H1 2027.

07 Financials, liquidity and dilution risk

June cash and securities were $170M, down $93.8M from year-end; H1 operating cash use was $81.288M and the $10M NEREUS milestone was an investing outflow. Total liabilities were $192.282M, so liquid assets are not all excess shareholder cash. Management expects funding through at least end-2027, conditional on revenues and lower expenses. June awards: 4,175,232 options at weighted $13.10, 4,002,478 unvested RSUs and 365,000 PSUs: 8,542,710 aggregate; 5,704,840 shares available for future grants. Vesting, exercise and performance conditions matter. The $200M mixed shelf is financing capacity, not an ATM by itself or cash raised.

SEC · Q2 2026

The Q2 filing also reports initial NEREUS wholesaler stocking and constrained revenue because patient demand and product returns remained uncertain with elevated channel inventory. The first $1.029 million of recognized revenue therefore establishes commercial sales, not a demonstrated recurring patient-demand rate. Subsequent dispensing, inventory and return disclosures are needed to interpret the launch. Q2 revenue-recognition disclosure

08 Regulatory history, management and governance

In August 2025, the D.C. Circuit set aside FDA’s refusal to hold a hearing on the HETLIOZ jet-lag supplemental application and remanded the matter. Vanda then announced an October 2025 collaborative framework with FDA addressing certain HETLIOZ and NEREUS disputes, including expedited re-review of that application. These procedural developments were not product approvals and sit alongside the later regulatory outcomes already discussed. Vanda Pharmaceuticals Q2 2026 Form 10-Q.

Timothy Williams notified Vanda on March 29, 2026 that he would resign as senior vice president, general counsel and secretary effective April 10 to pursue other endeavors, according to the April 2 8-K. Vanda Pharmaceuticals Q1 2026 Form 10-Q.

Management, governance and strategic optionality

Vanda was founded in 2003 and is led by Mihael H. Polymeropoulos, M.D., its co-founder, President, Chief Executive Officer and Chairman. The continuity is notable. Long-tenured founder-led biotech companies can be powerful when management has deep scientific conviction and can navigate difficult regulatory paths. They can also be controversial when shareholder impatience grows and the board is perceived as too aligned with management.

Governance is part of the VNDA story because the company has previously attracted unsolicited acquisition proposals. In 2024, Future Pak and Cycle Pharmaceutical pursued offers or proposals that Vanda rejected as undervaluing the company. Reuters reported that Future Pak eventually withdrew its offer, citing Vanda’s lack of engagement, after raising the cash portion of its proposed offer and maintaining contingent value rights. Vanda had also adopted a shareholder rights plan after earlier takeover pressure.

Those events still matter because VNDA’s asset base has changed. A company with Fanapt, HETLIOZ, PONVORY, NEREUS, approved BYSANTI and a pending imsidolimab PDUFA is not the same target as a company with older assets and unresolved late-stage filings. If new launches show traction, strategic interest could reappear. If they do not, activists or would-be acquirers may argue that the asset base would be better managed under a different structure. Either way, governance remains a source of optionality and risk.

On April 22, 2026, Vanda appointed Charles Duncan, Ph.D. to its board. The company stated that the board then consisted of seven directors, six of whom were independent. This is a useful governance data point, but investors will judge governance less by labels and more by capital allocation, launch execution, transparency and willingness to maximize shareholder value.

09 Catalyst and execution timeline

Execution and catalyst roadmap

May 1, 2026 — NEREUS launch

Commercial availability started in the United States.

August 5, 2026 — Q2 results and call

Reported: net product sales of $50.5 million, the first $1.0 million of NEREUS sales, cash and securities of $170.0 million at June 30, and 2026 revenue guidance of $240–290 million reiterated.

H2 2026 — BYSANTI rollout

Planned commercial availability and payer-access execution.

2026 — Thetis topline window

Results expected in 2026 in GLP-1 receptor agonist-induced vomiting, per the company’s August 5, 2026 guidance.

August 24, 2026 — EU orphan designation granted

European Commission designation for imsidolimab in GPP, completing the U.S., Japanese and EU orphan framework.

October 14, 2026 — VQW-765 Phase 3 misses primary endpoint

Study 3201 in social anxiety disorder did not meet its primary or key secondary endpoint; the program is on hold pending further analysis of the full dataset.

December 12, 2026 — Imsidolimab PDUFA

Late-year FDA decision for generalized pustular psoriasis.

September schedule: Wells Fargo September 8; Cantor September 11 at 08:00 ET; H.C. Wainwright September 15 at 10:00 ET; Morgan Stanley September 16. Investor conferences are not FDA action dates.

IR · September conferences

10 Bottom line

At the October 4, 2026 review, VNDA is a commercial-stage biotech with an unusually dense mix of revenue, launch risk and regulatory optionality. NEREUS is approved and on the market, BYSANTI is approved and scheduled for a H2 rollout, imsidolimab carries a December 12 PDUFA and now holds orphan designation in the United States, Japan and the European Union. Those are real assets and real milestones.